Bharat Biotech leads a CSIR-NMITLI supported project to develop human antibodies or COVID-19 therapy
On May 8, 2020, the Council of Scientific and Industrial Research (CSIR) under its flagship programme NMITLI announced…
-
-
Entos Pharma partnered with Precision NanoSystems to enable scalable GMP manufacturing of Fusogenix DNA COVID-19 vaccine
On May 7, 2020, Entos Pharmaceuticals announced a partnership with Precision NanoSystems, Inc., (PNI), a global leader in…
-
Air Force Genetics Laboratory, DHA collaborate to further sequence SARS-CoV-2 code
On May 11, 2020, the Air Force Genetics Center of Excellence at Keesler Air Force Base in Biloxi,…
-
Gilead announces approval of Veklury (remdesivir) in Japan for patients with severe COVID-19
On May 7, 2020, Gilead announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted…
-
First large study of hydroxychloroquine does not support routine use in COVID-19 patients
On May 7, 2020, a study of nearly 1,400 patients with moderate to severe COVID-19 disease at a…
-
Baxter announced results of clinical trial on benefits of Dynamic Fluid Management in septic shock patients
On May 6, 2020, Baxter announced results of the Fluid Response Evaluation in Sepsis Hypotension and Shock (FRESH)…
-
Mesoblast announced first patients dosed in phase 2/3 trial for COVID-19 ARDS
On May 6, 2020, Mesoblast announced that the first patients were dosed in the 300-patient randomized placebo-controlled Phase…
-
bioMerieux serology tests for SARS-CoV-2 on VIDAS underwent validation preceding launch
On May 6, 2020, bioMerieux announced performance validation and the upcoming launch of VIDAS® anti-SARS-CoV-2 serology tests to detect…
-
Laurent Pharmaceuticals received Health Canada’s approval to initiate COVID-19 clinical trial
On May 6, 2020, Laurent Pharmaceuticals announced that it has obtained the approval from Health Canada to initiate…
-
3M and Ford begin shipping newly designed powered air-purifying respirators for health care workers fighting COVID-19
On May 6, 2020, 3M and Ford announced that newly designed powered air-purifying respirators (PAPRs), developed are on…
-
Biotechnology | Diagnostics | Disease | FDA | Oncology | Therapeutics
FDA approved first targeted therapy to treat aggressive form of lung cancer
On May 6, 2020, the U.S. Food and Drug Administration (FDA) approved Tabrecta (capmatinib) for the treatment of…
-
Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
On May 5, 2020, Athersys announced that the first patients have been enrolled in Athersys’ pivotal Phase 2/3…
-
U.S. Dept. of Veterans Affairs Airborne Hazards and Open Burn Pit Registry reached major milestone
On May 5, 2020, the U.S. Dept. of Veterans Affairs (VA) announced the Airborne Hazards and Open Burn…
-
TGen and HonorHealth initiated COVID-19 combination therapy of atovaquone and azithromycin in patients with moderate-to-severe COVID-19 infection
On May 5, 2020, the HonorHealth Research Institute and HonorHealth announced the successful enrollment on a novel combination…
-
Innovation Pharma announced the next phase of Brilacidin Coronavirus testing begun
On May 5, 2020, Innovation Pharma reported it had executed executed a Material Transfer Agreement (MTA) with a…
-
Athersys announced commencement of patient enrollment in MACOVIA Study, a pivotal phase 2/3 trial evaluating MultiStem cell therapy for COVID-19 induced ARDS
On May 5, 2020, Athersys announced the first patients have been enrolled in Athersys’ pivotal Phase 2/3 study…
-
Biotechnology | COVID-19 | Diagnostics | Medical Device | Non-Profit Research | Pharmaceutical | Therapeutics
USPTO launched platform to facilitate connections between patent holders and potential licensees in key technologies
On May 4, 2020, the U.S. Patent and Trademark Office (USPTO) unveiled a new web-based intellectual property marketplace…
-
Vir and Alnylam identified RNAi therapeutic development candidate, VIR-2703 (ALN-COV), targeting SARS-CoV-2 for treatment of COVID-19
On May 4, 2020, Vir Biotech and Alnylam Pharma announced the selection of a development candidate for VIR-2703,…
-
Anixa Biosciences and OntoChem announced discovery of first Covid-19 therapeutic candidate
On May 4, 2020, Anixa Biosciences and partner OntoChem, announced they had identified its first therapeutic candidate against…
-
Cerus announced FDA approval for INTERCEPT Blood System for plasma with alternate plastic disposable kits
On May 4, 2020, Cerus announced U.S. Food and Drug Administration (FDA) regulatory approval for manufacture of INTERCEPT…
-
Eli Lilly and Junshi Biosciences to co-develop antibody therapies for pevention and treatment of COVID-19
On May 4, 2020, Junshi Biosciences and Eli Lilly announced they have entered into an agreement to co-develop therapeutic…
-
Mayo Clinic received $26 million from BARDA for COVID-19 convalescent plasma expanded access program
On May 4, 2020, Mayo Clinic was awarded a $26 million contract from the Biomedical Advanced Research and…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Non-Profit Research | Pharmaceutical | Therapeutics
Government of Canada Investing in global race to find a treatment for COVID-19
On May 3, 2020, the Government of Canada announced it was investing in projects that support the global…
-
FDA approved DARZALEX FASPRO, a new subcutaneous formulation of Daratumumab in treatment of patients with Multiple Myeloma
On May 1, 2020, the Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (DARZALEX FASPRO, Janssen Biotech.)…
-
CHF Solutions shipped Aquadex product to COVID-19 specialty center in Minnesota
On May 1, 2020, CHF Solutions announced that it has shipped Aquadex product to a specialty care center…
-
3M completed sale of its drug delivery business
On May 1, 2020, 3M announced that it has completed the sale of substantially all of its drug delivery…
-
XBiotech identified ‘super bloods’ for development of True Human COVID-19 therapy
On May 1, 2020, XBiotech announced that human immune donors have now been identified that can support the Company’s…
-
Gilead announced investigational antiviral remdesivir received FDA Emergency Use Authorization for treatment of COVID-19
On May 1, 2020, Gilead announced that the U.S. Food and Drug Administration (FDA) has granted emergency use…
-
FDA issued Emergency Use Authorization for potential COVID-19 treatment
On May 1, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for…
-
Timing of immune response to COVID-19 may contribute to disease severity
On May 1, 2020, a new University of Southern California (USC) study suggests that temporarily suppressing the body’s immune…
